Shield Therapeutics plc (STX.L)
LSE · GBp · Healthcare · Drug Manufacturers - Specialty & Generic
£5.30 (-3.64%) as of
Key statistics
- Market cap
- 56.93M
- Forward P/E
- 7.07
- EPS (TTM)
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- 3.70 – 12.50
- Beta
- 1.73
- Revenue (TTM)
- 58.62M
- Profit margin
- -17.69%
- Analyst target
- £16.67
- Volume
- 248.90k
About Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Gateshead, United Kingdom
- Employees
- 61
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.